Skip navigation

Practical Strategies for Risk Sharing and Performance Measurement Between Manufacturers and Payers

October 3-4, 2017
  • Philadelphia, PA

Life sciences manufacturers are facing heightened pressure from the government and other entities to lower the cost of drugs while improving patient outcomes. In an effort to shift from price-per-volume to high-value care, manufacturers are being tasked with bringing treatments to market with outcomes-based, risk-sharing agreements.

CLE
Credits
Available! Pending Approval

CBI’s Outcomes-Based Contracting Summit delivers key insights into the process of outlining, structuring and negotiating successful performance and value-based contracts. This conference also provides an excellent platform for manufacturers, payers and providers to discuss the challenges and successes regarding government price reporting, value optimization and price alignment with health outcomes data.

Solutions-Oriented Sessions Focused On:

  • Assessing the future impact of CMS’ newly proposed value-based care models on manufacturer responsibilities
  • Gaining an understanding of the risk-sharing
    challenges from the payer’s perspective
  • Identifying key considerations for partnering with ACOs
  • Mitigating risks associated with the provision and coordination of patient support services
  • Addressing performance-measuring questions via
    complex patient care scenarios
  • Discussing the challenges and rewards of co-developing drugs and diagnostics for enhanced outcomes

PREVIOUS ATTENDEE ACCLAIM:

With drug pricing practices now a cause célèbre in the US, it is imperative for pharmaceutical manufacturers to address these challenges as part of their value proposition. Making outcomes-based arrangements simple and workable for payers will be critical to mitigate additional price regulation and access restrictions that are being proposed by public and private payers, politicians, and other stakeholders.

“Raising the Stakes on Value-Based Pricing”, Pharmaceutical Executive, April 12th, 2016

October 3-4, 2017 The Wyndham Philadelphia, PA

Outcomes-Based Contracting Summit

Practical Strategies for Risk Sharing and Performance Measurement Between Manufacturers and Payers

Life sciences manufacturers are facing heightened pressure from the government and other entities to lower the cost of drugs while improving patient outcomes. In an effort to shift from price-per-volume to high-value care, manufacturers are being tasked with bringing treatments to market with outcomes-based, risk-sharing agreements.

CLE
Credits
Available! Pending Approval

CBI’s Outcomes-Based Contracting Summit delivers key insights into the process of outlining, structuring and negotiating successful performance and value-based contracts. This conference also provides an excellent platform for manufacturers, payers and providers to discuss the challenges and successes regarding government price reporting, value optimization and price alignment with health outcomes data.

Solutions-Oriented Sessions Focused On:

  • Assessing the future impact of CMS’ newly proposed value-based care models on manufacturer responsibilities
  • Gaining an understanding of the risk-sharing
    challenges from the payer’s perspective
  • Identifying key considerations for partnering with ACOs
  • Mitigating risks associated with the provision and coordination of patient support services
  • Addressing performance-measuring questions via
    complex patient care scenarios
  • Discussing the challenges and rewards of co-developing drugs and diagnostics for enhanced outcomes

PREVIOUS ATTENDEE ACCLAIM:

With drug pricing practices now a cause célèbre in the US, it is imperative for pharmaceutical manufacturers to address these challenges as part of their value proposition. Making outcomes-based arrangements simple and workable for payers will be critical to mitigate additional price regulation and access restrictions that are being proposed by public and private payers, politicians, and other stakeholders.

“Raising the Stakes on Value-Based Pricing”, Pharmaceutical Executive, April 12th, 2016

October 3-4, 2017 The Wyndham Philadelphia, PA